Nano-X Imaging Secures $15 Million in Registered Direct Offering

Nano-X Imaging Ltd. (NASDAQ: NNOX) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $15 million in gross proceeds. The company will sell 3,826,530 ordinary shares in this transaction, with Titan Partners Group, a division of American Capital Partners, serving as sole placement agent. Closing of the offering is anticipated on or about November 25, 2025, with net proceeds designated for working capital and general corporate purposes.

The funding comes as Nano-X continues its mission to transform preventive healthcare through accessible medical imaging technologies. The company's comprehensive ecosystem includes multiple integrated components designed to improve early disease detection and treatment outcomes. Central to this vision is the Nanox.ARC, a multi-source digital tomosynthesis system engineered to be both cost-effective and user-friendly, potentially expanding imaging access beyond traditional hospital settings.

Complementing the hardware platform is Nanox.AI LTD, which provides artificial intelligence algorithms that enhance the interpretation of routine CT imaging scans. These algorithms are designed to identify early indicators often associated with chronic diseases, potentially enabling earlier intervention and improved patient outcomes. The company's cloud infrastructure, Nanox.CLOUD, manages and stores data collected from Nanox devices while providing users with sophisticated tools for detailed imaging analysis.

Through its subsidiary USARAD Holdings Inc., Nano-X operates Nanox.MARKETPLACE, a proprietary decentralized platform that facilitates remote access to radiology and cardiology specialists. This comprehensive teleradiology services platform represents another component of the company's strategy to make specialized medical expertise more widely available. The integrated approach from scan to diagnosis reflects Nano-X's commitment to maintaining a clinically driven methodology throughout its technology development and deployment.

The $15 million capital infusion will support the company's ongoing efforts to advance its medical imaging technologies and expand their global reach. By focusing on affordability and accessibility, Nano-X aims to address current limitations in medical imaging availability, particularly in underserved regions. The company's vision extends beyond traditional healthcare settings, potentially bringing advanced diagnostic capabilities to locations where such resources have historically been limited.

For additional information about Nano-X Imaging and its medical imaging technologies, visit https://www.nanox.vision/. The recent funding announcement represents a significant step in the company's broader strategy to enhance preventive healthcare through technological innovation and expanded access to medical imaging services worldwide.